generally showed larger performance differences between congruent (or nonconflict) and incongruent (or conflict) trials than control participants, indicating impairments in conflict processing. In the current study, we examine whether dopaminergic medication modulates the ability of PD patients to adapt their cognitive control system in function of experienced conflict.
Previous studies on healthy subjects have demonstrated that the congruency effect is reduced after incongruent as compared to congruent trials (i.e., congruency sequence effect; e.g., Gratton, Coles, & Donchin, 1992) , as well as with increasing overall percentages of incongruent trials across the entire task (i.e., proportion congruency effect; e.g., Logan & Zbrodoff, 1979; Lowe & Mitterer, 1982) . These phenomena are regarded as indices of a specific domain of cognitive control, namely conflict adaptation. Conflict adaptation refers to the notion that cognitive control settings are adjusted upon detection of relatively large conflict, such that goal-directed behaviour is preserved in challenging situations where multiple incongruent action tendencies emerge (e.g., Abrahamse, Braem, Notebaert, & Verguts, 2016; Botvinick, Braver, Barch, Carter, & Cohen, 2001) . Prior work on conflict adaptation in PD has shown mixed outcomes, with some studies reporting reduced or absent conflict adaptation (i.e., congruency sequence effects : Cagigas, Filoteo, Stricker, Rilling, & Friedrich, 2007; Fielding, Georgiou, Bradshaw, Millist, & White, 2005; Praamstra & Plat, 2001; Rustamov et al., 2013 ; proportion congruency effects : Bonnin, Houeto, Gil, & Bouquet, 2010) , and others observing intact conflict adaptation in terms of the congruency sequence effect (i.e., Wylie et al., 2010) . Critically, these studies could not dissociate disease-related from medication-related DA effects as patients were tested either ON (Bonnin et al., 2010; Cagigas et al., 2007; Fielding et al., 2005; Rustamov et al., 2013; Wylie et al., 2010) or OFF (Praamstra & Plat, 2001 ) their regular dopaminergic medication regimen and the effect of medication status was not systematically considered. Duthoo et al. (2013) proposed that the ambiguous findings regarding conflict adaptation in PD may be due to the neglect of medication status as a contributing factor. They suggested that impairments in conflict adaptation in PD could be related to the DA overdose hypothesis (Cools, Barker, Sahakian, & Robbins, 2001 ; for a review, see Vaillancourt, Schonfeld, Kwak, Bohnen, & Seidler, 2013) . This hypothesis holds that dopaminergic medication restores DA levels within the depleted dorsal striatum and connected areas including the supplementary motor area (SMA) and premotor cortex (PMC), consequently improving functions related to these areas (such as general motor functioning). However, at the same time medication may cause a DA overdose in the relatively spared ventral striatum and connected areas, including the prefrontal cortex (PFC) and anterior cingulate cortex (ACC). Neuroimaging studies demonstrated the importance of these areas for conflict processing and adaptation (e.g., Botvinick, Cohen, & Carter, 2004; Botvinick et al., 2001; Grandjean et al., 2013) . Hence, conflict adaptation may be impaired as a result of dopaminergic medication. In line with this hypothesis, Duthoo et al. (2013) showed that the congruency sequence effect was observed when PD patients were tested OFF medication, but not when patients were tested ON medication.
The present study aimed to (conceptually) replicate and extend Duthoo et al.'s work (2013) by evaluating for the first time the effect of dopaminergic medication in PD on proportion congruency-based conflict adaptation. Hence, rather than focusing on the effect of previous trial congruency , we examined the impact of medication status on adaptation in PD to a list-wide proportion congruency manipulation. Besides the question whether such proportion congruency-based conflict adaptation emerges in PD (which before has only been tested once; Bonnin et al., 2010) , we were especially interested to evaluate whether dopaminergic medication modulated this effect. Previous work has proposed that cognitive control processes, including conflict adaptation, may be grounded in associative learning across active perceptual, motor, and goal representations. Verguts & Notebaert, 2008 . Upon detection of cognitive conflict, associations between these representations are strengthened such that people learn to prioritize certain types of information in high-conflict situations and can use this information to anticipate the action that is most appropriate. According to this view, conflict adaptation effects due to previous trial congruency and overall proportion congruency thus both build on the same mechanism. Inspired by the study by Duthoo et al. (2013) and the DA overdose hypothesis, we therefore predict that medication status will modulate the proportion congruency effect in PD patients. To test this prediction, PD patients performed a Stroop task in which they respond to the ink colour in which colour words are printed. The combinations of ink colour and colour word were either congruent (e.g., the word 'green' printed in green ink) or incongruent (e.g., 'green' in red ink). Participants' performance was evaluated by studying mouse movement trajectories. Compared to simple, discrete responses (e.g., key-press or verbal response), these mouse responses allow us to investigate which movement parameters (initiation time, movement time, and movement accuracy) are sensitive to medication status and proportion congruency. The task comprised two blocks: one block included mostly congruent trials, and a second block included mostly incongruent trials. To investigate the effect of medication on proportion congruency-based conflict adaptation, PD patients performed the experiment once ON and once OFF their medication. We expected to observe a smaller (or even absent) proportion congruency effect for Stroop task performance ON compared to OFF medication.
Method
Patient sample Fifteen patients diagnosed with PD (11 male, four female) aged between 51 and 70 years participated in the study.
1 They were in the mild to moderate stages of the disease (Hoehn and Yahr stages 1-2; Hoehn & Yahr, 1967) . According to the Montreal Cognitive Assessment (MoCA), one patient showed signs for PD dementia with an average score (ON and OFF medication) below the cut-off of 21 (Dalrymple-Alford et al., 2010) . The data from this patient were therefore excluded from further analyses. The analyses below thus were performed on the data of 14 patients, whose demographic and clinical characteristics are listed in Table 1 .
Patients' verbal intelligence was estimated with the Dutch version of the National Adult Reading Test. Scores indicated that IQ estimates were within the normal range (M = 106.50 AE 7.35). According to the Beck Depression Inventory-II (BDI-II-NL), 11 of the patients in our sample scored in the minimally depressed range, one scored in the mildly depressed range, and two scored in the moderately depressed range. None of the patients showed indications of severe depression. As mentioned above, patients performed the experiment during two separate sessions, allowing us to test the effect of dopaminergic medication. For each patient, we calculated the levodopa equivalent dose (LED; see Tomlinson et al., 2010) to compare different medication regimens among patients. Twelve patients were treated with levodopa, in ten cases coupled with a DA agonist. Of these ten patients, seven additionally received rasagiline, a monoamine oxidase-B inhibitor, and two patients were additionally treated with a catechol-O-methyl transferase inhibitor. The two patients who did not take levodopa were treated with a combination of a DA agonist and rasagiline.
To assess patients' motor symptoms ON and OFF medication, we administered the motor part of the Unified Parkinson's Disease Rating Scale (UPDRS) on each session. UPDRS scores indicated that medication significantly alleviated motor symptoms, t (13) = 6.13, p < .001 (see Table 1 ). To evaluate potential differences in patients' mood state between the sessions, we administered the Profile of Mood States (POMS) questionnaire. Within-subject comparison of the two scores, ON (M = 16.64 AE 12.43) and OFF medication (M = 26.64 AE 25.99) showed no significant difference, t (13) = 1.86, p = .085.
All patients provided written informed consent and received €25 per test session for their participation. The study was approved by the Ethical Board of the local University Hospital.
Apparatus
Stimulus presentation, timing and data recording were controlled by MouseTracker software (Freeman & Ambady, 2010) , running on a Dell Latitude E5540 laptop computer. Stimuli were displayed on a separate 24-in LCD monitor connected to the laptop, running at a 1,440 9 900 resolution (60 Hz refresh rate). A standard computer mouse was used for responding, with the cursor speed set at the 6/11 default mode in Windows 7. 
Stroop task
Four response boxes (4 9 5 cm) were presented at the far-left, centre-left, centre-right, and far-right in the upper half of a computer screen (see Figure 1 ). Each box contained a colour word (from left to right, the Dutch words for red, blue, yellow, and green), printed in white. At the beginning of each trial, a start button (2 9 5 cm) appeared at the lower centre of the screen. Upon clicking on the button with the mouse, a stimulus appeared just above the start button after a 300-ms interval. As soon as participants clicked the start button, the mouse cursor was automatically relocated to the centre of this button with (x, y)-coordinates of (0,0.16), so that mouse movements always began from the same location on each trial. Stimuli consisted of four Dutch colour words for red, blue, yellow, and green. They were printed in one of the same four ink colours and presented against a back background (see Figure 1 ). The words red and green were always printed in either red or green, and the words blue and yellow always in either blue or yellow. These words and ink colours were paired so that the response boxes relating to task-relevant and task-irrelevant stimulus features during incongruent trials were on opposite sides of the computer screen; far-left was always linked to far-right, and centre-left was always linked to centreright, in terms of colour-pairing. Patients thus had to commit to moving the cursor to either the left or right side of the screen, which optimized the tracking of conflict processing as reflected in mouse trajectories. The task also included neutral trials, consisting of symbols (e.g., # and &) printed in one of the four ink colours. These trials were included to examine if and how general motor performance was affected by our proportion congruency manipulation.
Patients were instructed to respond to the ink colour of a presented stimulus by moving the mouse as quickly as possible into a response box, and clicking the box to register their choice. The response boxes remained visible throughout the experiment. A trial ended when patients clicked one of the response boxes. The intertrial interval was 500 ms, after which the start button could be clicked again. In case of an incorrect response, a red X would appear in the centre of the screen for 2 s, after which participants could start the next trial. Participants could use their preferred hand for responding, with the restriction that they would use the same hand during both test sessions (three used their left hand, the others their right hand).
In a brief practice session, each patient performed 24 trials (eight congruent, incongruent, and neutral trials, randomly presented) to become familiar with the task and check whether they correctly understood the instructions. They then performed two experimental blocks, either involving mostly congruent (i.e., the MC block) or mostly incongruent Stroop stimuli (i.e., the MI block). The MC block was always performed first to enhance the effect on behaviour of the proportion congruency manipulation: Abrahamse, Duthoo, Notebaert, and Risko (2013) have shown that the proportion congruency effect is smaller when starting with a MI block (i.e., asymmetric list shifting effect). Each block included the randomly ordered presentation of 112 congruent, 20 incongruent, and 48 neutral trials (numbers for congruent and incongruent trials were reversed for the MI block).
Procedure
As mentioned above, patients performed the experimental tasks once ON and once OFF their dopaminergic medication (1-week interval). Whereas seven patients were first tested without making any changes to their medication regimen, seven other patients first performed the tasks after overnight withdrawal from their medication. Testing always took place in the morning. Before the start of the first session, participants were briefed about the procedure. During each session, they completed a short interview and questionnaires and performed the experimental task. Finally, the motor part of the UPDRS-III was administered.
Data processing
Real-time x-and y-coordinates of the mouse cursor were recorded every 13-16 ms during each trial. In addition, the initiation time (IT; time between stimulus presentation and movement onset) and movement time (MT; time between movement onset and clicking the response box) were logged. Using the trajectory data, we then determined the area under the curve (AUC); this is the standardized geometric area between the recorded mouse trajectory and the optimal trajectory (i.e., a straight line from the start button to the correct response box), which reflects the overall attraction towards other response alternatives (for details, see Freeman & Ambady, 2010) . The first trial of each block, and error and post-error trials were omitted from the analyses. We also excluded trials when the MT exceeded the mean MT of a patient by more than three standard deviations. This was done separately for the neutral, congruent, and incongruent trials per block and per medication status, resulting in the removal of 1.6% of the trials. For each patient, we then calculated mean IT, MT, and AUC per medication status and block for the neutral, congruent, and incongruent trials. We did not analyse patients' performance in terms of incorrect responses, as across all patients only 26 errors were made; 21 on incongruent trials, four on neutral trials, and one on a congruent trial.
Results

General motor performance
We performed separate repeated-measures analysis of variance (ANOVA) for each of our dependent variables on neutral trials only with Medication Status (2; ON vs. OFF) and Block (2; MC vs. MI) as within-subject variables. Results showed that MT was shorter when patients were ON compared to OFF their medication (2,214 vs. 2,540 ms), F (1, 13) = 4.69, p = .049, g 2 p = .26. This effect of Medication Status was further modulated by Block, F (1, 13) = 9.44, p = .009, g 2 p = .42. Follow-up analyses showed that the beneficial effect of medication on MT was only observed in the MI block (MT ON = 2,178, MT OFF = 2,600 ms), F (1, 13) = 6.85, p = .021, g 2 p = .34, but not the MC block (MT ON = 2,250 ms, MT OFF = 2,479 ms; F (1, 13) = 2.48, p = .13, g 2 p = .16). There were no significant effects on IT (M = 225, SE = 5; ps > .072) or AUC (M = .13, SE = .004; ps > .19).
Conflict adaptation
To analyse patients' performance during Stroop trials, we ran repeated-measures ANOVAs separately for each of our dependent variables with Trial Type (2; congruent vs. incongruent), Block (2), and Medication Status (2) as within-subject variables. The results of these ANOVAs are presented in Table 2 .
Results showed several simple main effects. First, main effects of Trial Type indicated that MT was shorter for congruent than incongruent trials (2,345 vs. 2,646 ms), F (1, 13) = 58.89, p < .001, g 2 p = .82, and that AUC was smaller for congruent than incongruent trials (.108 vs. .197), F (1, 13) = 7.29, p = .018, g 2 p = .36). Second, a main effect of Block for AUC showed that mouse movements deviated more from the optimal trajectory in the MC block than in the MI block (.178 vs. .127), F (1, 13) = 5.24, p = .038, g 2 p = .28. Finally, while results showed no main effects of Medication Status on IT (ON = 202 ms, OFF = 263 ms, p = .14) or AUC (ON = .15, OFF = .15, p = .95), we observed that MT was shorter ON compared to OFF medication (2,318 vs. 2,673 ms), F (1, 13) = 5.08, p = .042, g 2 p = .28. Results further showed Trial Type 9 Block interactions (i.e., the proportion congruency effect) for both MT, F (1, 13) = 38.68, p < .001, g 2 p = .75, and AUC, F (1, 13) = 8.11, p = .014, g 2 p = .38, but not for IT (p = .35). Figure 2 shows MT (top row, left (Cousineau, 2005; Morey, 2008) . Follow-up analyses showed that MT was shorter for congruent than incongruent trials in both the MC block (2,289 vs. 2,778 ms), F (1, 13) = 78.72, p < .001, g 2 p = .86, and the MI block (2,401 vs. 2,513 ms), F (1, 13) = 6.84, p = .021, g 2 p = .34. A paired t-test comparing the MT difference between the congruent and incongruent trials for performance in the MC vs. MI block revealed that the congruency effect was larger in the MC block than the MI block (488 ms vs. 113 ms), t (13) = 6.22, p < .001. We observed a similar pattern of results for AUC. Specifically, AUC was smaller for congruent than incongruent trials in both the MC block (.110 vs. .247), F (1, 13) = 7.79, p = .015, g 2 p = .37, and the MI block (.107 vs. .147), F (1, 13) = 5.00, p = .043, g 2 p = .28. A paired t-test showed that the congruency effect was larger in the MC block than the MI block (.14 vs. .04), t (13) = 2.85, p = .014.
Results showed no significant interactions among Trial Type, Block, and Medication Status for any of our dependent variables (ps > .32). To evaluate whether the proportion congruency effect was present in both the ON and OFF states, we performed separate repeated-measures ANOVAs on MT and AUC with Trial Type (2) and Block (2) as withinsubject variables for each medication status. For MT, results revealed that the Trial Type 9 Block interaction was significant both ON medication, F (1, 13) = 15.77, p = .002, g 2 p = .55, and OFF medication, F (1, 13) = 15.68, p = .002, g 2 p = .55. Please note that even when controlling for baseline differences in MT between performance ON and OFF medication (i.e., by dividing for each patient the proportion congruency effect by baseline MT, separately for the ON and OFF states), results showed no significant effect of medication on the proportion congruency effect (t = À.13, p = .89). For AUC, significant Trial Type 9 Block interactions were observed both ON medication, F (1, 13) = 5.01, p = .043, g 2 p = .28, and OFF medication, F (1, 13) = 8.06, p = .014, g 2 p = .38. As Figure 2 (centre and right panels) shows, these interactions were in line with the proportion congruency effect.
Post-hoc Bayesian analyses
To determine whether the lack of significant three-way interactions should be interpreted as evidence for the absence of an effect of medication status on the proportion congruency effect, we reanalysed our data using a Bayesian approach. For each dependent variable, we calculated the Bayes factor (BF 01 ) using a Bayesian repeated-measures ANOVA test with default prior settings in the JASP software package (JASP Team, 2017; Rouder, Morey, Verhagen, Swagman, & Wagenmakers, 2017) . A BF 01 larger than 3 is regarded as moderate evidence for the null hypothesis (with > 10 being strong evidence), a BF 01 between 1 and 3 as merely anecdotal evidence, and a BF 01 smaller than 0.3 is regarded as evidence for the alternative hypothesis (Dienes, 2011; Jeffreys, 1961) . The BFs for the three-way interaction as reflected in IT, MT, and AUC (BF 01 = 3.675, BF 01 = 3.443, and BF 01 = 3.141, respectively) indicated that the current data provide moderate evidence for the absence of an effect of dopaminergic medication on the proportion congruency effect.
Discussion
The current study investigated for the first time the effect of dopaminergic medication on conflict adaptation in PD using mouse tracking. First, we observed reliable proportion congruency effects in PD patients both ON and OFF their medication. To our best knowledge, this is a first for both medication states, although our results are in direct contrast to those of Bonnin et al. (2010) for the ON medication state. Second, we observed that the proportion congruency effect did not change reliably as a function of medication status. Indeed, results of post-hoc Bayesian analyses provided moderate evidence for the null hypothesis that the proportion congruency effect did not differ between PD patients ON and OFF their medication. This contrasts our hypothesis, as we predicted that a medication-induced DA overdose in brain areas that are involved in conflict adaptation (e.g., ventral striatum and connected areas, including PFC and ACC) would have a detrimental effect on the emergence of a proportion congruency effect. Below, we first briefly discuss the discrepancy between our current and previous findings. We then focus in more detail on our findings regarding the absence of a medication effect on the proportion congruency effect and the implications for the dopamine overdose hypothesis in relationship to various types of conflict adaptation.
The current observation of a proportion congruency effect both ON and OFF medication contrasts an earlier study on the proportion congruency effect in PD (Bonnin et al., 2010) , where the effect was absent in PD patients who were ON their medication (note that patients were not tested OFF their medication). This discrepancy between the current and previous findings may be related to the responses that were used in each study. Bonnin et al. (2010) employed key-press responses and consequently could not differentiate between the initiation time component and the actual movement time component of the total response time. Additionally, they could not study movement accuracy during the development of patients' responses, which may have obscured conflict adaptation effects. The use of continuous mouse movements in the present study allowed us to evaluate more sensitive movement parameters and detect proportion congruency-based conflict adaptation as reflected in MT and AUC.
Conceptually, the current findings also contrast those by Duthoo et al. (2013) , who reported reliable conflict adaptation in PD patients when tested OFF but not ON medication. These different findings may pertain to the specific manipulations used to study conflict adaptation, with Duthoo et al. (2013) evaluating effects of previous trial congruency and the current study employing a list-wide proportion congruency manipulation. The differential impact of medication status implies that adaptation following previous trial versus list-wide proportion congruency manipulations may derive from distinct control systems, rather than from the same mechanism Verguts & Notebaert, 2008 . Indeed, various researchers have assumed such a distinction, claiming that the congruency sequence effect reflects transient conflict adaptation, whereas the proportion congruency effects can be considered to reflect a more sustained type of conflict adaptation (Funes, Lupi añez, & Humphreys, 2010; TorresQuesada, Funes, & Lupi añez, 2013) . According to this view, it could be argued that the differential manipulations to induce conflict adaptation between the current study and Duthoo et al.'s (2013) study drive different attentional adjustments. Specifically, whereas the present study examined the proportion congruency effect, which relates to sustained adaptation in which attentional settings are optimized based on the overall congruency context of an entire block (Bugg & Crump, 2012) , Duthoo et al. (2013) studied the congruency sequence effect, which involves trial-by-trial fluctuations in attentional demand.
In spite of behavioural indications that these types of adaptation rely on separate attentional control systems (Funes et al., 2010; Torres-Quesada et al., 2013) , the discrepancy between our current and the previous findings seems remarkable as both control mechanisms are thought to involve the dorsolateral PFC (DLPFC; e.g., Braver, 2012; Braver, Paxton, Locke, & Barch, 2009; Bugg & Crump, 2012; Kim, Johnson, & Gold, 2014; Krug & Carter, 2012) and thus could be hypothesized to be similarly affected by dopaminergic medication. At the neural level, a potential explanation for the differential sensitivity to dopaminergic medication of transient versus sustained control mechanisms is that they may have differential optimal DA levels. Evidence for the existence of differential, control-specific optimal DA levels in PD was recently provided by Fallon et al. (2015) , who reported indications that the optimal DA level in PD may be higher for setshifting than for working memory tasks -even though both processes are known to rely on the DLPFC. Potentially, dopaminergic medication may impair the ability to flexibly update task goals in PD (cf. congruency sequence effect; Duthoo et al., 2013; Rustamov et al., 2013 ) by exceeding the optimal DA level, but not the ability to update task goals in a more sustained fashion (cf. proportion congruency effect; present study). Admittedly, this notion is speculative and should be systematically examined in future studies.
In line with the literature, we observed that dopaminergic medication improved patients' motor performance in the current study. The beneficial effect of medication was reflected in shorter movement times for responses to both neutral trials and Stroop trials, as well as lower UPDRS scores ON medication. Unexpectedly, however, we found that for neutral trials the effect of medication was modulated by our proportion congruency manipulation. Specifically, the effect of medication status was observed only for the MI block; for the MC block, it showed the expected direction, but improvement was not significant. This modulation suggests that the effects of our manipulations related to medication status (ON vs. OFF) and cognitive control context (MC vs. MI) on performance somehow interacted, even though this selectively emerged for one type of trial (neutral trials) and for one dependent variable (movement time). This selectivity prevents firm conclusions, because the finding is not easy to link to either recent cognitive control theories (e.g., Abrahamse et al., 2016; Braver, 2012; Shenhav, Botvinick, & Cohen, 2013; Verguts & Notebaert, 2008 or the dopamine overdose hypothesis (Cools et al., 2001; Vaillancourt et al., 2013) . Nonetheless, the here observed interaction between medication status and our cognitive control manipulation should inspire future exploration.
A limitation of the current study is that while the effect of medication status on mood was not significant, we cannot irrefutably exclude a role for mood in the here observed effects of medication on performance. Given previous indications that mood may be associated with DA levels (Ashby, Isen, & Turken, 1999) and that PD patients report better mood when being ON compared to OFF their medication (Menza, Sage, Marshall, Cody, & Duvoisin, 1990 ; but see Duthoo et al., 2013) , we acknowledge the possibility that medication effects were mediated by mood. Another limitation relates to our decision to always present the MC block before the MI block, to optimize the design for observing a proportion congruency effect (Abrahamse et al., 2013) . Specifically, as a result our proportion congruency manipulation was confounded with practice on the task. As previous studies have indicated that the Stroop effect decreases with prolonged practice (e.g., Davidson, Zacks, & Williams, 2003; MacLeod, 1998) , one might argue that a practice effect by itself could explain the observed proportion congruency effect -with no need to assume conflict adaptation. To address this issue, we divided each block of the present experiment into six time bins. We then calculated the size of the congruency effect for each time bin (in MT and AUC). As Figure 3 illustrates, the congruency effect decreases rather sharply when the MI block is introduced. Moreover, if practice by itself would underlie our results, the proportion congruency effect should be stronger with increasing time-on-task differences between the MC and MI blocks (i.e., stronger effect for the dark bars in Figure 3 than the light bars). To test this, we repeated our main ANOVAs with Practice (2; dark vs. light bars) as additional within-subject variable. For both MT and AUC, results showed that size of the proportion congruency effect was not significantly modulated by Practice (MT p = .77; AUC p = .15). This argues against an explanation of the present results in terms of practice and corroborates that conflict adaptation was driven by our proportion congruency manipulation.
Overall, the present study demonstrates that the proportion congruency effect in the Stroop task is reflected in continuous mouse movements performed by PD patients. We found no indications that dopaminergic medication modulated sustained conflict adaptation as indicated by the proportion congruency effect in PD. This contrasts earlier work showing that medication impaired transient conflict adaptation as reflected in the congruency sequence effect in PD . Our findings thus suggest that more sustained as opposed to transient cognitive control processes may not be sensitive to dopamine overdose effects. Alternatively, the absence of overdose effects could indicate that sustained adaptation is governed by the dorsal striatum -however, in that case one might have expected to observe beneficial effects of dopaminergic medication. Another interpretation of the current findings may be that sustained adaptation is not critically dependent upon the dopaminergic system, yet this would contrast predictions from models on conflict adaptation (Braver & Cohen, 2000; Holroyd & Coles, 2002) . The current results further refine our understanding of the role of DA in cognitive control processes in PD. Furthermore, they may ultimately help clinicians in determining optimal medication regimens for PD patients, by considering individual patient priorities regarding the effect of dopaminergic treatments on motor versus cognitive functioning. To that end, future studies should further examine the differential effect of dopaminergic medication on flexible versus sustained cognitive control mechanisms in relationship to potential differential optimal DA levels for these mechanisms in PD.
